Sangamo Therapeutics Logo

Sangamo Therapeutics Appoints Adrian Woolfson, BM., B.Ch., Ph.D., As Executive Vice President Of Research And Development

January 22, 2019

RICHMOND, Calif., Jan. 22, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Adrian Woolfson, BM BCh, PhD, as Executive Vice President of Research and Development, effective January 22, 2019. Dr. Woolfson will oversee discovery, research and development activities for the Company and will report to Sandy Macrae.

"This is a meaningful time to welcome Adrian to Sangamo, as we expect a significant flow of clinical data from our genomic medicines programs throughout 2019 and will advance new programs into first-in-human studies," said Sandy Macrae, Sangamo's Chief Executive Officer. "Adrian's extensive experience in research, translational medicine and drug development will be instrumental in guiding our therapeutic development strategy and leading Sangamo's growth into a late-stage development company in the upcoming years."

Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Most recently, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company's off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer's hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio encompassing a broad range of immuno-modulatory agents focused on the Pfizer/Merck KGaA PD-L1 inhibitor avelumab and 4-1BB agonist utomilumab. Prior to that he was the Global Lead for Pfizer's SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb initially in London, UK where he launched the TKI dasatinib, and then in Princeton, New Jersey, where he was Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibitor.

Before joining industry, Dr. Woolfson completed his post-graduate training in internal medicine at Addenbrooke's Hospital Cambridge in the UK. He holds a BM BCh degree in Clinical Medicine from Oxford University and completed his PhD in molecular immunology at Cambridge University in the UK. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and a Wellcome Trust Clinical Research Fellow. His doctoral and post-doctoral work on alternative splicing, soluble CD antigens, and protein folding was in the laboratory of Nobel Prize winner and inventor of monoclonal antibodies Dr César Milstein in the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology in Cambridge, UK.

About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. For more information about Sangamo, visit www.sangamo.com.

Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include, without limitation, the expectation of significant flow of clinical data throughout 2019, the Company's advancement of new programs into first-in-human studies, and that Adrian's extensive experience will be instrumental in guiding our therapeutic development strategy. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the uncertainty in the timing of enrollment and clinical data, the dependence on the success of clinical trials of lead programs, the lengthy and uncertain regulatory approval process, uncertainties related to the initiation and completion of clinical trials, whether the final results from the clinical studies will validate and support the safety and efficacy of product candidates, Sangamo's reliance on partners and other third-parties to meet their clinical and manufacturing obligations, and the ability to maintain strategic partnerships. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-appoints-adrian-woolfson-bm-bch-phd-as-executive-vice-president-of-research-and-development-300782301.html

SOURCE Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc., Investors: McDavid Stilwell, 510-970-6000, x219, mstilwell@sangamo.com or Varant Shirvanian, 510-970-6000 x205, vshirvanian@sangamo.com; Media: Aron Feingold, 510-970-6000, x421, afeingold@sangamo.com